跳至主導覽 跳至搜尋 跳過主要內容

Primary bone marrow diffuse large B cell lymphoma: A case series and review

  • Hung Chang
  • , Yu Shin Hung
  • , Tung Liang Lin
  • , Po Nan Wang
  • , Ming Chung Kuo
  • , Tzung Chih Tang
  • , Jin Hou Wu
  • , Po Dunn
  • , Lee Yung Shih*
  • *此作品的通信作者
  • Chang Gung Memorial Hospital
  • Chang Gung University

研究成果: 期刊稿件 › 文獻綜述 › 同儕審查

42 引文 斯高帕斯(Scopus)

摘要

Diffuse large cell lymphoma involving bone marrow is not uncommon, but primary, de novo, bone marrow diffuse large B cell lymphoma (DLBCL) is rare. To understand the clinical features and outcomes of this distinct entity, we collected 12 cases in 5 years from a single-center database. They accounted for 1.16% of lymphoma, or 2.65% of diffuse large B cell lymphoma. Nine cases presented with fever of unknown origin. Lactate dehydrogenase levels were elevated in all but one case. Nine cases belonged to the high-risk group according to their international prognosis indexes (score 4 or 5). Four patients received no chemotherapy, all of whom died within 1 month. Four patients received cyclophosphamide, adriamycin, vincristine, and prednisolone (CHOP)-like chemotherapy, and their median survival was 13 months. Finally, four patients received rituximab 375 mg/m2 in addition to CHOP-like chemotherapy. All of them had complete remission and three are still alive without relapse. We concluded that primary bone marrow DLBCL is a rare but distinctive subtype of lymphoma. The prognosis for this entity is poor but rituximab-based treatment is promising for improving its outcomes.

原文英語
頁(從 - 到)791-796
頁數6
期刊Annals of Hematology
卷90
發行號7
DOIs
出版品狀態已出版 - 07 2011
對外發佈是

UN SDG

此研究成果有助於以下永續發展目標

  1. SDG3 健康與福祉
    SDG3 健康與福祉

指紋

深入研究「Primary bone marrow diffuse large B cell lymphoma: A case series and review」主題。共同形成了獨特的指紋。

引用此